EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 613-619

  Fischer Colbrie, Jutta ^a,b   Witt, Armin ^a   Heinzl, Harald ^a   Speiser, Paul ^a   Czerwenka, Klaus ^a   Sevelda, Paul ^a   Zeillinger, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Epidermal growth factor receptor; Ovarian carcinoma; Steroid receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031056372     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sevelda P, Vavra N, Schemper M and Salzer H: Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer 65: 2349-2352, 1990.
2. Sevelda P, Schemper M and Spona J: CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am Obstet Gynecol 161: 1213-1216, 1989.
3. Scambia G, Catozzi L, Panici PB, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A and Mancuso S: Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol 1993.
4. Simpson BJ, Weatherill J, Miller EP, Lessells AM, Langdon SP and Miller WR: c-erbB3 protein expression in ovarian tumours. Br J Cancer 71: 758-62, 1995.
5. Sevelda P, Denison U, Schemper M, Spona J, Vavra N and Salzer H: Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma. Br J Obstetr Gynecol 97: 706-712, 1990.
6. Scambia G, Benedetti PP, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A and Mancuso S: Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361-366, 1995.
7. Wimalasena J, Dostal R and Meehan D: Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 46: 758-62, 1992.
8. Owens OJ, Stewart C and Leake RE: Growth factors in ovarian cancer. Br J Cancer 64: 1177-1181, 1991.
9. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast Jr RC and Boyer CM: The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 75: 255-262, 1990.
10. Crew AJ, Langdon SP, Miller EP and Miller WR: Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines. Eur J Cancer 28: 337-441, 1992.
11. Derynck R: Transforming growth factor alpha. Cell 54: 593-595, 1988.
12. Smith JA, Barraclough R, Fernig DG and Rudland PS: Identification of alpha transforming growth factor as a possible local trophic agent for the mammary gland. J Cell Physiol 141: 362-370, 1989.
13. Laurence DJ and Gusterson BA: The epidermal growth factor. A review of structural and functional relationships in the normal organism and in cancer cells. Tumour Biol 11: 229-261, 1990.
14. Downward J, Parker P and Waterfield MD: Autophosphorylation sites on the epidermal growth factor receptor. Nature 311: 483-485, 1984.
15. Carpenter G: Properties of the receptor for epidermal growth factor. Cell 37: 357-358, 1984.
16. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermalgrowth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987.
17. Bauknecht T, Kohler M, Janz I and Pfleiderer A: The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endomelrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol 115: 193-199, 1989.
18. Owens OJ, Stewart C, Brown I and Leake RE: Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br J Cancer 64: 907-910, 1991.
19. Scambia G, Benedetti PP, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, De VR and Mancuso S: Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 10: 529-35, 1992.
20. Stewart CJ, Owens OJ, Richmond JA and McNicol AM: Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 11: 266-272, 1992.
21. Kurachi H, Morishige K, Amemiya K, Adachi H, Hirota K, Miyake A and Tanizawa O: Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res 51: 5956-5959, 1991.
22. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Pearson-Clarke DL and Bast Jr RC: The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 767: 1877-1882, 1992.
23. Ferrandina G, Scambia G, Benedetti-Panici P, Bonanno G, De Vincenzo R, Rumi C, Bussa S, Genuardi M, Romano-Spica V and Mancuso S: Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. Mol. Cell Endocrinol 83: 183-193, 1992.
24. Bauknecht T, Runge M, Schwall M and Pfleiderer A: Occurrence of epidermal growth factor (EGF-R) in human adn exal tumors and their prognostic value in advanced ovarian carcinoms. Gynecol. Oncol 29: 147-159, 1988.
25. Van der Burg MEL, Henzen-Logmans SC, Foekens JA, Berns EMJJ, Rodenburg CJ, Van Putten WLJ and Klijn JGM: The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer 29A1: 1951-1957, 1993.
26. Serov SF, Scully RE and Sorbin LH: Histological typing of ovarian tumors. In: (eds.), International Histological Classification of Tumors. Geneva: World Health Organization, 1973, pp.
27. Day TG, Gallagher HS and Rudledge FN: Epithelial carcinoma of the ovary: the prognostic importance of histologic grade. Natl Cancer Inst Monogr 42: 15-21, 1975.
28. Grill HJ, Manz B and Pollow K: Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors. Oncology 41: 25-32, 1984.
29. Scatchard G: The attraction of proteins for small molecules and ions. Ann. NY Acad. Sci. 51: 660-665, 1949.
30. Oberkanins C, Geurts-Moespot A, Zeillinger R, Kury F, Leake RE and Benraad TJ: The performance of a commercial radioligand binding assay for the epidermal growth factor receptor is comparable to the EORTC standard assay. Eur J Cancer 31A: 1710-1711, 1995.
31. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
32. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
33. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep 50: 163-170, 1966.
34. Cox DR: Regression models and life tables. J Royal Stat Soc B 34: 187-220, 1972.
35. Nicholson S, Sainshurv JRS, Needham GK, chambers P, Farndon JR and Harris AL: Quantitative assays of epidermal growth factor receptor in human breast cancer: Cutoff points of clinical relevance. Int J Cancer 42: 36-41, 1988.
36. Richardson GS, Scully RE, Nikrui N and Nelson Jr. JH: Common epithelial cancer of the ovary. N Engl J Med 312: 415-424, 1985.
37. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N and Boyes DA: Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264-270, 1985.
38. Rao BR and Slotman BJ: Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12: 14-26, 1991.
39. Bauknecht T, Birmelin G and Kommoss F: Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem. Mol Biol 37: 855-862, 1990.
40. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL and Bast Jr RC: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164: 669-674, 1991.
41. Christen RD, Horn DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L and Howell SB: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86: 1632-1640, 1990.
42. Lang T, Daxenbichler G and Marth C: Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. Anticancer Res 14: 1871-1874, 1994.
43. Pegram MD, Pietras RJ, Chazin VR, Ellis L and Slamon DJ: Effect of erb-B2 (HER2/neu) overexpression on chemotherapeutic drug sensitivity in human breast cancer and ovarian cancer cells. Proc. 84th Ann. Meeting of the Am Ass for Cancer Res 34: A152, 1993.
44. Wolf J, Yu D, Hung MC and Price JE: Increased chemosensitivity of human ovarian cancer cells with reduced p185 expression. Proc. 84th Ann Meeting of the Am Ass for Cancer Res 34: A313, 1993.
45. Slotman BJ, Nauta JJP and Rao BR: Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 66: 740-744, 1990.
46. Freedman RS, Saul PB, Ewdards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN and Dana WJ: Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study. Cancer Treat Rep 70: 369-373, 1986.
47. Schwartz PE, Chambers JT, Kohorn EI, Chambers SK, Weitzman H, Voynick IM, MacLusky N and Naftolin F: Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 63: 1074-1078, 1989.